Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Raises Price Target to $251

Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc.

AXSM

0.00

Morgan Stanley analyst Sean Laaman maintains Axsome Therapeutics (NASDAQ: AXSM) with a Equal-Weight and raises the price target from $242 to $251.